The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03248219
Recruitment Status :
First Posted : August 14, 2017
Last Update Posted : June 20, 2018
University of Colorado, Denver
Center for Womens Health Research at University of Colorado Anschutz Medical Campus
College of Nursing at University of Colorado Anschutz Medical Campus
Colorado Clinical & Translational Sciences Institute
Sleep disordered breathing (SDB) insidiously worsens metabolic function, heightens insulin resistance (IR), and in pregnancy is thought to precipitate gestational diabetes, preterm birth, growth restriction, gestational hypertension, and preeclampsia. Despite the fact that sleep disturbances are common during pregnancy, SDB remains under-recognized, under-diagnosed, and poorly understood, particularly in pregnancies affected by obesity. Sixty percent of pregnancies are now affected by obesity, yet the relationship between SDB, patterns of glycemia, and insulin resistance (IR) in obese pregnant women is a neglected area with major therapeutic implications to improve maternal and infant health. Using a prospective design in which diet and gestational age are highly controlled, the investigators propose to measure SDB (apneas/hypopneas) in obese pregnant women using an ambulatory sleep monitoring system. In parallel, robust patterns of glycemia will be measured with a continuous glucose monitoring system (CGMS), followed by a 75g oral glucose tolerance test to measure insulin action. The investigators global hypothesis is that worse SDB in part accounts for higher 24-hour patterns of glycemia in obese normal glucose tolerant (NGT) pregnant women in their 3rd trimester. The Investigators will test the hypothesis that: 1) In obese NGT pregnant women at 32-34 weeks gestation on a controlled eucaloric diet, higher apnea hypopnea index (AHI) will be positively associated with 24-hour glycemia measured by a CGMS and that, 2) Higher AHI in obese NGT pregnant women at 32-34 weeks gestation on a eucaloric controlled diet will be associated with higher insulin resistance measured by a 75g oral glucose tolerance test (Matsuda Model). Early identification and treatment has the potential to decrease long-term maternal cardiovascular morbidity and mortality.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 39 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pregnant women who are 32-34 weeks pregnant who live in the Denver Metro Area
Between the ages of 20-39 yrs,
At 32-34 weeks gestation,
Who have a BMI of ≥30 to ≤40 kg/m2,
Who have a singleton pregnancy, and
Who have a normal glucose tolerance test on entrance to the study.
Who have a diagnosis of diabetes (GDM, type 1 or type 2),
Who are using beta blockers/glucocorticoids.
Who have other children who are ≤2 yrs old (due to risk of disrupted sleep),
With diagnosed sleep disorders (e.g. OSA, insomnia, restless leg syndrome),
Who work night or rotating shifts,
Who report use of sleep medications will be excluded,
With diagnosed pulmonary or cardiovascular disease